In fiscal year 2019 , the Japanese pharmaceutical company Daiichi Sankyo generated a revenue of almost 982 billion Japanese yen , up from approximately 930 billion yen in the previous fiscal year . The Tokyo-based company researches in the field of innovative drugs , with subsidiaries operating worldwide .
